MedTrace Logo

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

NCT00003380 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-06-10

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of liposomal doxorubicin and etoposide in treating patients who have recurrent or persistent ovarian, fallopian tube, or peritoneal cancer.

Conditions

Interventions

DRUG

etoposide

DRUG

pegylated liposomal doxorubicin hydrochloride

Sponsors & Collaborators

  • Gynecologic Oncology Group

    lead NETWORK

  • National Cancer Institute (NCI)

    collaborator NIH

Principal Investigators

  • Peter G. Rose, MD · The Cleveland Clinic

Study Design

Purpose
TREATMENT

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Primary Completion
2002-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003380 on ClinicalTrials.gov